Evidence map›Paper›PMID 35796933›Full record

ArticleJournal of neuro-oncology2022

Mid-term treatment-related cognitive sequelae in glioma patients.

Sabine Schlömer, Jörg Felsberg, Milena Pertz, Bettina Hentschel, Markus Löffler, Gabriele Schackert, Dietmar Krex, Tareq Juratli, Joerg Christian Tonn, Oliver Schnell and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 2 countries.

Sabine SchlömerDepartment of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892, Bochum, Germany. sabine.schloemer@kk-bochum.de.ORCID http://orcid.org/0000-0001-8237-8004
Jörg FelsbergInstitute of Neuropathology, Heinrich Heine University Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.
Milena PertzDepartment of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892, Bochum, Germany.
Bettina HentschelInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Markus LöfflerInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Gabriele SchackertDepartment of Neurosurgery, University Hospital, University Carl Gustav Carus of Dresden, Dresden, Germany.
Dietmar KrexDepartment of Neurosurgery, University Hospital, University Carl Gustav Carus of Dresden, Dresden, Germany.
Tareq JuratliDepartment of Neurosurgery, University Hospital, University Carl Gustav Carus of Dresden, Dresden, Germany.
Joerg Christian TonnDepartment of Neurosurgery, University Hospital, Ludwig Maximilians University of Munich, Munich, Germany.
Oliver SchnellDepartment of Neurosurgery, University Hospital, Ludwig Maximilians University of Munich, Munich, Germany.
Hartmut VatterDepartment of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Matthias SimonDepartment of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Manfred WestphalDepartment of Neurosurgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Tobias MartensDepartment of Neurosurgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Michael SabelDepartment of Neurosurgery, Heinrich Heine University Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.
Martin BendszusDepartment of Neuroradiology, Medical Center of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Nils DörnerDepartment of Neuroradiology, Medical Center of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Klaus FliessbachDepartment of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
Christian HoppeDepartment of Epileptology, University Hospital Bonn, Bonn, Germany.
Guido ReifenbergerInstitute of Neuropathology, Heinrich Heine University Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Uwe SchlegelDepartment of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892, Bochum, Germany.
For The German Glioma Network
University Hospital Bonn · DEDüsseldorf University Hospital · DEUniversitätsklinikum Knappschaftskrankenhaus Bochum · DEUniversity Hospital Carl Gustav Carus · DEHeidelberg University · DELeipzig University · DEUniversität Hamburg · DELudwig-Maximilians-Universität München · DEUniversity of Freiburg · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCognitive functioning represents an essential determinant of quality of life. Since significant advances in neuro-oncological treatment have led to prolonged survival it is important to reliably identify possible treatment-related neurocognitive dysfunction in brain tumor patients. Therefore, the present study specifically evaluates the effects of standard treatment modalities on neurocognitive functions in glioma patients within two years after surgery.

methodsEighty-six patients with World Health Organization (WHO) grade 1-4 gliomas were treated between 2004 and 2012 and prospectively followed within the German Glioma Network. They received serial neuropsychological assessment of attention, memory and executive functions using the computer-based test battery NeuroCog FX. As the primary outcome the extent of change in cognitive performance over time was compared between patients who received radiotherapy, chemotherapy or combined radio-chemotherapy and patients without any adjuvant therapy. Additionally, the effect of irradiation and chemotherapy was assessed in subgroup analyses. Furthermore, the potential impact of the extent of tumor resection and histopathological characteristics on cognitive functioning were referred to as secondary outcomes.

resultsAfter a median of 16.8 (range 5.9-31.1) months between post-surgery baseline neuropsychological assessment and follow-up assessment, all treatment groups showed numerical and often even statistically significant improvement in all cognitive domains. The extent of change in cognitive functioning showed no difference between treatment groups. Concerning figural memory only, irradiated patients showed less improvement than non-irradiated patients (p = 0.029, η

conclusionWithin a two-year post-surgery interval, radiotherapy, chemotherapy or their combination as standard treatment did not have a detrimental effect on cognitive functions in WHO grade 1-4 glioma patients. Cognitive performance in patients with adjuvant treatment was comparable to that of patients without.

Indexed as

Brain NeoplasmsGliomaCognitionDisease ProgressionHumansNeuropsychological TestsQuality of LifeGliomaNeuroCog FXNeuropsychological assessmentProspectiveTreatment-related neurotoxicity

Identifiers

PMID35796933
PMCPMC9325813
OpenAlexW4284888134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.